Avalo Therapeutics CFO Christopher Ryan Sullivan disposes of 12,394 common shares for $202,436.79
Bitget2026/09/18 20:10- Avalo Therapeutics CFO Christopher Ryan Sullivan sold 12,394 common shares at USD 16.33 on Sep. 16, 2026.
- Sale followed the exercise of stock options for 12,394 shares at USD 9.88.
- Directly held common shares fell to 39,900.
- Directly held stock options rose to 83,848.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
As US Treasury yields rise, the cost of borrowing short-term Treasuries surges, with traders aggressively building short positions
The US Treasury will conduct auctions of two-year, five-year, and seven-year Treasury bonds next week. Currently, traders are racing to borrow bonds to short them, driving the borrowing costs for short-term Treasuries sharply higher. On Friday, the overnight repo rate for borrowing the current two-year Treasury was about 0.79%, while the rate for the five-year even dropped to as low as -0.85%. In contrast, the repo rate for regular Treasuries was around 3.88%.
Concentrix EVP Cormac Twomey to step down effective Dec. 31, 2026
Accenture, Anthropic To Build Embedded AI Evaluator Team
VO ETF Falls 0.2%
Crypto prices
More
